Breaking News

Teva, Lonza JV Cool On Biosimilars

April 5, 2013

Will evaluate regulatory, commercial circumstances before further investment

Teva and Lonza are re-evaluating the potential of their joint venture to develop, manufacture and market biosimilars. The companies are exploring the best routes to realizing the benefits of biosimilars for certain biologics. With regulatory uncertainty in the biosimilars arena, both companies are taking a measured approach to fully evaluate regulatory and commercial circumstances before agreeing on further long-term investments.
blog comments powered by Disqus
  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors

  • Platinum Press Facility Tour

    Platinum Press Facility Tour

    Kristin Brooks, Contract Pharma||March 23, 2016
    Opens doors to new, 47,000-sq.-ft. packaging facility in Oakland, NJ

  • Biopharma Packaging Equipment Close-up

    Biopharma Packaging Equipment Close-up

    Kristin Brooks, Contract Pharma||March 7, 2016
    Sieghard Schuchmann of OPTIMA discusses biopharma trends impacting packaging equipment, and the latest capabilities

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Getting Real

    Michael Pollock, PPD||November 17, 2015
    Partnering for clinical and real-world evidence studies

  • Bringing Transparency and Collaboration to CRO Oversight

    Bringing Transparency and Collaboration to CRO Oversight

    Craig Morgan , goBalto Inc. ||November 17, 2015
    Relationships between sponsors and CROs are getting stronger